The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis
Stuttering is a DSM V psychiatric condition for which there are no FDA-approved medications for treatment. A growing body of evidence suggests that dopamine antagonist medications are effective in reducing the severity of stuttering symptoms. Stuttering shares many similarities to Tourette’s Syndrom...
Main Authors: | Gerald A. Maguire, Diem L. Nguyen, Kevin C. Simonson, Troy L. Kurz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-03-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2020.00158/full |
Similar Items
-
Olanzapine versus haloperidol: Which can control stuttering better?
by: Vahid Shaygannejad, et al.
Published: (2013-01-01) -
Investigation of Risperidone Treatment Associated With Enhanced Brain Activity in Patients Who Stutter
by: Gerald A. Maguire, et al.
Published: (2021-02-01) -
Report of a Rare Case of Olanzapine and Risperidone Induced Hypomania
by: AR Zahiroddin, et al.
Published: (2006-07-01) -
Comparative study of adverse effects of Olanzapine and Risperidone on blood suger, lipid and other side effects in psychotic disorders
by: mitra safa, et al.
Published: (2008-10-01) -
The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
by: Liang Y, et al.
Published: (2017-04-01)